us fda panel drug approval recommendations

Download US FDA panel drug approval recommendations

Post on 22-Mar-2017




3 download

Embed Size (px)


  • 22

    US FDA panel drug approval recommendations

    Dual therapies for H. pylori eradication endorsed The US FDA's advisory committees on anti-infective

    and gastrointestinal drugs have recommended the approval of two types of dual-therapy for the eradication of Helicobacter pylori infection in patients with peptic ulcer disease, reports the Wall Street Journal. I

    These therapies are clarithromycin ['Biaxin'; Abbon Laboratories] + omeprazoJe ('Prilosec'; Astra Merck Inc.1, and c1arithromycin + ranitidine bismutrex ['Tritec'; Glaxo Wellcome]. However. the comminees recommended against the approval of ranitidine bismutrex + amoxicillin as data on the efficacy of this combination therapy were inconclusive.

    Reoommendatiom for ophtbahnic products Pharmacia & Upjohn's topical prostaglandin

    Iatanoprost ['Xalatan'] has been recommended for approvaJ by the FDA's Ophthalmic Drugs Subcommittee for the reduction of intraocular pressure in patients with open-angle glaucoma and ocular hypertension, according to the Pink Shut. 2

    The subcommiuee voted 4-2 to recommend the approval of Iatanoprost; the 2 votes against approval were due to the risk of iridial pigmentation associated with use of the drug. Pharmacia & Upjohn plan to assess the risk of iridial pigmentation in 4 post-marketing studies.

    The FDA's Ophthalmic and Dermatologic Advisory Committee has recommended the approval of Chiron Vi sion's sterile intravitreal ganciclovir implant 'Vitrasert ' in patients with cytomegalovirus (CMV) retinitis.) In a study involving patients with newly-diagnosed AIDS-related CMV retinitis, the agent delayed time to progression of the disease by 112 days, compared with IV ganciclovir.

    "The implant is p/Qcai irI the posterior segnv:nr of the noIoc: 8, II Dec 1m 3. 0Iir0D VJtrUUI tilDe 10 ~ is 194 dI)'I ill phase m IriaI; opbthalrrlie impIaDt IO::Ww:c:ndo>d for awrovaI by FDA Advitary Comrninee. FDC Reports - Pink SbceI - PretaipioD I'ba-mIceuIicab aDd B~ 7. II Dc